IQVIA (IQV) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
27 Oct, 2026Executive summary
Q3 revenue was $4.428B, up 8.0% reported and 8.6% at constant currency; adjusted EBITDA rose 8.7% and adjusted diluted EPS rose 11.3%, exceeding guidance highs.
Organic growth accelerated in both segments; R&D bookings reached a four-year high, with margin expansion and higher win rates supporting momentum.
FY2026 revenue, adjusted EBITDA and adjusted diluted EPS guidance was raised.
Financial highlights
Q3 adjusted EBITDA was $1.032B; adjusted net income was $557M and adjusted diluted EPS was $3.34, up 11.3% YoY.
Q3 GAAP diluted EPS was $2.10; net income attributable to common stockholders was $350M.
Nine-month revenue was $12.947B, up 8.4% reported and 7.7% at constant currency; adjusted EBITDA was $2.958B and adjusted diluted EPS was $9.38, up 10.4%.
Nine-month adjusted net income was $1.576B; GAAP net income attributable to common stockholders was $880M.
Q3 operating cash flow was $825M, capex was $158M and free cash flow was $667M, equal to 120% of adjusted net income.
Outlook and guidance
FY2026 revenue guidance was raised to $17.350B–$17.500B, or 6.4%–7.3% growth; adjusted EBITDA guidance to $4.025B–$4.055B, or 6.3%–7%.
FY2026 adjusted diluted EPS guidance was raised to $12.90–$13.00, or 8.2%–9.1% growth.
Revenue guidance includes ~250 bps of acquisition contribution and ~20 bps of FX tailwind; guidance assumes October 26, 2026 exchange rates persist.
Adjusted EBITDA margin is expected to be flat YoY at ~23.2%; Q4 assumptions include ~$210M net interest expense, D&A just over $160M and ~169M diluted shares.
Q4 revenue has an implied ~70 bps FX headwind; 2027 detailed guidance is scheduled for February 2027.
Latest events from IQVIA
- FY23 growth and a $29.7B R&D backlog support FY24 revenue and EPS guidance.IQV
Q4 2023 - Q2 2026 revenue and earnings grew strongly, leading to raised full-year guidance.IQV
Q2 2026 - Strong Q4 growth, robust AI-driven strategy, and stable margins support a positive outlook.IQV
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day - Strong Q1 results, AI-driven growth, and rising demand signal industry recovery and expansion.IQV
Jefferies Global Healthcare Conference 2026 - Strong Q1 growth, accelerating AI adoption, and robust capital deployment signal positive outlook.IQV
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue up 8.4%, net income $274M, and full-year EPS guidance raised.IQV
Q1 2026 - Q2 2025 revenue rose 5.3% with robust segment growth, capital actions, and AI-driven innovation.IQV
Q2 2025 - Q2 revenue rose 2.3% to $3.814B, with strong R&D growth, record backlog, and raised guidance.IQV
Q2 2024 - Q1 2025 revenue up 2.5% to $3.83B; guidance raised; strong TAS and R&D performance.IQV
Q1 2025